Pulmonary Metastasectomy in Colorectal Cancer: A Population-Based Retrospective Cohort Study Using the Korean National Health Insurance Database

被引:13
|
作者
Yu, Woo Sik [1 ]
Bae, Mi Kyung [2 ]
Choi, Jung Kyu [3 ]
Hong, Young Ki [4 ]
Park, In Kyu [5 ]
机构
[1] Ajou Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Suwon, South Korea
[2] Natl Hlth Insurance Serv Ilsan Hosp, Dept Thorac & Cardiovasc Surg, Goyang, South Korea
[3] Natl Hlth Insurance Serv Ilsan Hosp, Inst Hlth Insurance & Clin Res, Goyang, South Korea
[4] Natl Hlth Insurance Serv Ilsan Hosp, Dept Gen Surg, Goyang, South Korea
[5] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Thorac & Cardiovasc Surg, 101 Daehak Ro, Seoul 03080, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2021年 / 53卷 / 04期
关键词
  Survival; Prognosis; Lung; Metastasectomy; Colorectal neoplasms; CURATIVE RESECTION; SURGICAL RESECTION; LUNG METASTASES; SURVIVAL; OUTCOMES; VOLUME; CHEMOTHERAPY; PROGNOSIS; CARE;
D O I
10.4143/crt.2020.1213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The study aimed to investigate the current status and prognostic factors for overall survival in patients who had undergone pulmonary metastasectomy for colorectal cancer. Materials and Methods The data of 2,573 patients who had undergone pulmonary metastasectomy after surgery for colorectal cancer between January 2009 and December 2014 were extracted from the Korean National Health Insurance Service claims database. Patient-, colorectal cancer-, pulmonary metastasis-, and hospital-related factors were analyzed using the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis to identify prognostic factors for overall survival after pulmonary metastasectomy. Results The mean age of the patients was 60.9 +/- 10.5 years; 66.2% and 79.1% of the participants were male and had distally located colorectal cancer, respectively. Wedge resection (71.7%) was the most frequent extent of pulmonary resection; 21.8% of the patients underwent repeated pulmonary metastasectomies; 73% of pulmonary metastasectomy cases were performed in tertiary hospitals; 53.9% of patients were treated in Seoul area; 82% of patients received chemotherapy in conjunction with pulmonary metastasectomy. The median survival duration was 51.8 months. The 3- and 5-year overall survival rates were 67.7% and 39.4%, respectively. In multivariate analysis, female sex, distally located colorectal cancer, pulmonary metastasectomy-only treatment, and high hospital volume (> 10 pulmonary metastasectomy cases/yr) were positive prognostic factors for survival. Conclusion Pulmonary metastasectomy seemed to provide long-term survival of patients with colorectal cancer. The female sex, presence of distally located colorectal cancer, and performance of pulmonary metastasectomy in high-volume centers were positive prognostic factors for survival.
引用
收藏
页码:1104 / 1112
页数:9
相关论文
共 50 条
  • [31] The value of tumor deposits in evaluating colorectal cancer survival and metastasis: a population-based retrospective cohort study
    Wenhao Wu
    Shun Zeng
    Xianbin Zhang
    Peng Liu
    Tong Qiu
    Shulin Li
    Peng Gong
    World Journal of Surgical Oncology, 20
  • [32] Prognoses of different pathological subtypes of colorectal cancer at different stages: A population-based retrospective cohort study
    Xiaoli Wu
    Han Lin
    Shaotang Li
    BMC Gastroenterology, 19
  • [33] The value of tumor deposits in evaluating colorectal cancer survival and metastasis: a population-based retrospective cohort study
    Wu, Wenhao
    Zeng, Shun
    Zhang, Xianbin
    Liu, Peng
    Qiu, Tong
    Li, Shulin
    Gong, Peng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [34] The Impact of Sarcopenia Onset Prior to Cancer Diagnosis on Cancer Survival: A National Population-Based Cohort Study Using Propensity Score Matching
    Su, Chih-Hsiung
    Chen, Wan-Ming
    Chen, Ming-Chih
    Shia, Ben-Chang
    Wu, Szu-Yuan
    NUTRIENTS, 2023, 15 (05)
  • [35] Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study
    Zheng, C.
    Jiang, F.
    Lin, H.
    Li, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11) : 1524 - 1531
  • [36] Alcohol consumption and survival of colorectal cancer patients: a population-based study from Germany
    Walter, Viola
    Jansen, Lina
    Ulrich, Alexis
    Roth, Wilfried
    Blaeker, Hendrik
    Chang-Claude, Jenny
    Hoffmeister, Michael
    Brenner, Hermann
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2016, 103 (06) : 1497 - 1506
  • [37] National practice patterns and direct medical costs for prostate cancer in Korea across a 10year period: a nationwide population-based study using a national health insurance database
    Kang, Ho Won
    Yun, Seok-Joong
    Chung, Jae Il
    Choi, Hoon
    Kim, Jae Heon
    Yu, Ho Song
    Ha, Yun-Sok
    Cho, In-Chang
    Kim, Hyung Joon
    Chung, Hyun Chul
    Koh, Jun Sung
    Kim, Wun-Jae
    Park, Jong-Hyock
    Lee, Ji Youl
    Kim, So-Young
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [38] Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national population database in the United States
    Hao, Scarlett
    Snyder, Rebecca A.
    Irish, William
    Parikh, Alexander A.
    PLOS MEDICINE, 2021, 18 (10)
  • [39] Physical activity and survival of colorectal cancer patients: Population-based study from Germany
    Walter, Viola
    Jansen, Lina
    Knebel, Philip
    Chang-Claude, Jenny
    Hoffmeister, Michael
    Brenner, Hermann
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 1985 - 1997
  • [40] Association of cancer diagnosis with disability status among older survivors of colorectal cancer: a population-based retrospective cohort study
    Zhang, Shiming
    Chou, Lin-Na
    Swartz, Michael D.
    Mehta, Hemalkumar B.
    Goodwin, James S.
    Kuo, Yong-Fang
    Giordano, Sharon Hermes
    Tucker, Carole A.
    Basen-Engquist, Karen M.
    Lyons, Elizabeth J.
    Downer, Brian
    Peterson, Susan K.
    Cao, Tru
    Swartz, Maria C.
    FRONTIERS IN ONCOLOGY, 2024, 14